Company Profile

Veloxis Pharmaceuticals (OTC: VXPZY)
Pricing data not available
Detailed Quote
Open: $ n/a   Volume: n/a
High: $ n/a   Yield(%) n/a
Low: $ n/a   P/E Ratio (ttm): n/a
Dividend ($): n/a   Market Cap ($): n/a
EPS ($) n/a   Shares Out: n/a
M = Million B = Billion
Price Performance
% Price Change (last 4 weeks): n/a
% Price Change (last 13 weeks): n/a
% Price Change (last 26 weeks): n/a
% Price Change (last 52 weeks): n/a
% Price Change (year to date): n/a
Management Effectiveness
Return on Equity (%): n/a
Return on Assets (%): n/a
Return on Invested Capital (%): n/a
Profitability
Gross Profit Margin (%): n/a
Net Profit Margin (%): n/a
Operating Profit Margin (%): n/a
Price & Volume
50-day Moving Average: $n/a
200-day Moving Average: $n/a
Avg. Daily Vol. (last 50 days): n/a
Avg. Daily Vol. (last 200 days): n/a
52-wk high: $n/a
52-wk low: $n/a
Bid: $n/a
Ask: $n/a
Company Information
Veloxis Pharmaceuticals A/S is a commercial-stage specialty pharmaceutical company, which engages in the development and commercialization of medicine for the prevention of organ rejection in kidney transplant patients. The company is focused on the direct commercialization of Envarsus XR in the US, expansion of partnerships for markets, and acquisition of assets utilized in transplant patients and by adjacent medical specialties. Veloxis Pharmaceuticals was founded in June 2002 and is headquartered in Copenhagen, Denmark.
Veloxis Pharmaceuticals
Amerika Plads 37
Copenhagen CR 2100

Phone: 45.70.33.33.00
Fax: 45.36.13.03.19
http://www.veloxis.com
Per Share Data
Earnings (1year) ($): 0.38
Annual Dividend ($): 0.00
Current P/E Ratio (ttm): n/a
Book Value ($): n/a
Cash Flow ($): n/a
Valuation Ratios
Price/Earnings (x): n/a
Price/Sales (x): n/a
Price/Book (x): n/a
Price/Cash Flow (x): n/a
Financial Strength
Quick Ratio (x): n/a
Current Ratio (x): n/a
LT Debt/Equity (x): n/a
Total Debt/Equity (x): n/a



Quotes displayed with 15 minutes delay. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions. Legal Statement. News provided by MT Newswires, a Division of MidnightTrader, Inc. Events Data provided by Wall Street Horizon. ©2020 Wall Street Horizon, Inc.